BioSpace News Archive

Job Trends

What You Need to Know to Become a Medical Science Liaison

BioSpace spoke with Dr. Samuel Dyer, CEO of The MSL Society, to find out everything you need to know to become a medical science liaison.

January 21, 2019
·
2 min read
·
Editorial Team
Business

GSK Chairman Sir Philip Hampton Steps Down Ahead of Company Split

Hampton has served as chairman of the board since 2015. He decided to part ways with the company as it plans to separate into two entities.

January 21, 2019
·
2 min read
·
Alex Keown
Business

OCR and ImaBiotech initiate a strategic partnership to provide in situ drug efficacy and target exposure services in Pets with naturally occurring tumors

OCR and ImaBiotech have announced the launch of a new preclinical service for Biotech-Pharma-MedTech companies that allows drug efficacy and target exposure services at cellular level using Pets with naturally occurring tumors.

January 21, 2019
·
4 min read
Novo Nordisk Investment Fund Backs Companies Developing Therapies Combatting Antimicrobial Resistance

Novo Nordisk’s investment arm, Novo Holdings, invested a little more than $20 million in four different companies over the course of 2018 through its REPAIR Impact Fund. That $165 million fund was established last year to support companies developing therapies to combat antimicrobial resistance.

January 21, 2019
·
2 min read
·
Alex Keown
Policy

Chinese Government Takes Action Against CRISPR Researcher

China government officials told the Xinhua News Agency that the researcher who became world famous for using CRISPR on human embryos “will be transferred to public security authorities,” and the individuals involved in the research will be “severely dealt with according to the law.”

January 21, 2019
·
2 min read
·
Mark Terry
Deals

Kindred Biosciences Announces Pricing of Public Offering of 4,215,000 Shares of its Common Stock

Kindred Biosciences, Inc. today announced the pricing of an underwritten public offering of 4,215,000 shares of its common stock at a public offering price of $9.50 per share

January 21, 2019
·
5 min read
FDA

Samsung Bioepis’ First Cancer Biosimilar Approved by the FDA

The U.S. Food and Drug Administration (FDA) approved South Korea’s Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar to Genentech’s Herceptin (trastuzumab).

January 21, 2019
·
3 min read
·
Mark Terry
Biotech Bay

Your Feedback Matters! Applying for Jobs

As a valued member of our BioSpace community, we are eager to hear more from you and other readers in 2019. Which channel is better when applying for jobs?

January 21, 2019
·
1 min read
·
BioSpace Staff
BioForest

Physician-Targeted Marketing Is Associated With Increase in Opioid Overdose Deaths

While lawsuits against opioid manufacturers wind their way through the courts, the new study shows a direct link to marketing efforts and overdoses.

January 21, 2019
·
3 min read
·
Alex Keown
FDA

FDA User Fees Will Run out by Feb. 8, Causing Delay in Drug Approvals Unless Shutdown Ends

The partial government shutdown is 31 days old, yet the U.S. Food and Drug Administration has maintained a steady list of drug approvals throughout that time. However, that approval rate could change next month.

January 21, 2019
·
2 min read
·
Alex Keown